ArticleEnvironmental health and preventive medicine2025
Validation of the Japanese version of MemScreen: a rapid screening tool for mild cognitive impairment.
Article in Environmental health and preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was to examine the validity of the Japanese version of MemScreen (MemScreen-J), a touchscreen MCI screening test. 20 patients with MCI aged 65-90 years at the Juntendo Tokyo Koto Geriatric Medical Center were recruited as cases in December 2023. Non-cases were recruited from local residents in Toon City, Ehime Prefecture in February 2024 and 40 residents, without a medical history of MCI, aged 58-84 years were included in the present study. MemScreen-J test, a self-administered screening test in the form of a digital application, downloadable on a tablet, was administered to participants to assess their cognitive function. Defining the group at high risk of MCI based on a MemScreen-J test score of 28 or lower achieved the best Youden index in the study sample, with a sensitivity of 0.75 and a specificity of 0.98. MemScreen-J appeared to be a valid screening tool among persons at the prodromal stage of dementia, given reasonably high accuracy in detection of MCI. This innovative neuropsychological test could be the first step in a diagnostic approach to cognitive complaints in a community, identifying persons at the preclinical stage of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.